HomeCompareSILK vs ORCC

SILK vs ORCC: Dividend Comparison 2026

SILK yields 7.28% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SILK wins by $11.0K in total portfolio value
10 years
SILK
SILK
● Live price
7.28%
Share price
$27.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$1,154.32
Full SILK calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — SILK vs ORCC

📍 SILK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSILKORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SILK + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SILK pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SILK
Annual income on $10K today (after 15% tax)
$618.41/yr
After 10yr DRIP, annual income (after tax)
$981.17/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, SILK beats the other by $980.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SILK + ORCC for your $10,000?

SILK: 50%ORCC: 50%
100% ORCC50/50100% SILK
Portfolio after 10yr
$26.9K
Annual income
$577.68/yr
Blended yield
2.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

SILK
Analyst Ratings
3
Buy
7
Hold
3
Sell
Consensus: Hold
Price Target
$30.58
+11.2% upside vs current
Range: $20.00 — $46.00
Altman Z
4.6
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SILK buys
0
ORCC buys
0
No recent congressional trades found for SILK or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSILKORCC
Forward yield7.28%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$32.4K$21.4K
Annual income after 10y$1,154.32$1.04
Total dividends collected$9.5K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$30.58$16.00

Year-by-year: SILK vs ORCC ($10,000, DRIP)

YearSILK PortfolioSILK Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$11,428$727.54$11,190$489.61+$238.00SILK
2$13,004$777.01$12,229$256.01+$775.00SILK
3$14,741$826.38$13,216$130.74+$1.5KSILK
4$16,649$875.46$14,207$66.02+$2.4KSILK
5$18,738$924.05$15,234$33.17+$3.5KSILK
6$21,022$971.98$16,317$16.62+$4.7KSILK
7$23,512$1,019.10$17,468$8.32+$6.0KSILK
8$26,223$1,065.28$18,695$4.16+$7.5KSILK
9$29,169$1,110.38$20,006$2.08+$9.2KSILK
10$32,366$1,154.32$21,407$1.04+$11.0KSILK

SILK vs ORCC: Complete Analysis 2026

SILKStock

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Full SILK Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this SILK vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SILK vs SCHDSILK vs JEPISILK vs OSILK vs KOSILK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.